Kiniksa Pharmaceuticals International
- Country
- 🇧🇲Bermuda
- Ownership
- -
- Employees
- 297
- Market Cap
- $1.9B
- Introduction
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.
Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Kiniksa Pharmaceuticals, Ltd.
- Target Recruit Count
- 145
- Registration Number
- NCT05198310
- Locations
- 🇿🇦
Jacaranda Hospital, Pretoria, Gauteng, South Africa
🇿🇦Clinresco Centres (Pty) Ltd, Kempton Park, Gauteng, South Africa
🇿🇦Umhlanga Hospital Medical Center, Umhlanga, Kwazulu-Natal, South Africa
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Kiniksa Pharmaceuticals, Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT04497662
- Locations
- 🇦🇺
Q-Pharm Pty Ltd, Herston, Queensland, Australia
🇺🇸PPD Clinic, Austin, Texas, United States
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Kiniksa Pharmaceuticals, Ltd.
- Target Recruit Count
- 815
- Registration Number
- NCT04447469
- Locations
- 🇵🇪
Hospital Nacional Cayetano Heredia, San MartÃn De Porres, Peru
🇧🇷Hospital Cardio Pulmonar, Salvador, Bahia, Brazil
🇺🇸UCLA Medical Center, Los Angeles, California, United States
A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
- Conditions
- Interventions
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- Kiniksa Pharmaceuticals, Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT03858634
- Locations
- 🇺🇸
Site 114, Hot Springs, Arkansas, United States
🇺🇸Site 105, Normal, Illinois, United States
🇺🇸Site 120, Gainesville, Florida, United States
KPL-301 for Subjects With Giant Cell Arteritis
- Conditions
- Interventions
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Kiniksa Pharmaceuticals, Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT03827018
- Locations
- 🇪🇪
Site 2402, Tartu, Estonia
🇺🇸Site 1707, Lansing, Michigan, United States
🇬🇧Site 1602, London, United Kingdom
Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Kiniksa Pharmaceuticals, Ltd.
- Target Recruit Count
- 190
- Registration Number
- NCT03816891
- Locations
- 🇧🇪
Site 2701, Liège, Belgium
🇩🇪Site 2011, Dresden, Germany
🇩🇪Site 2008, Göttingen, Germany